NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 991 DKK | +1.15% |
|
+0.71% | +41.96% |
| 06-14 | Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy | RE |
| 06-14 | Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup | DJ |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.96% | 630B | |
| +50.70% | 791B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +1.27% | 225B | |
| +11.95% | 218B | |
| +3.68% | 160B | |
| -4.38% | 156B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Faces Second Fire at Danish Headquarters Within a Week
